Aptevo Historical Financial Ratios
| APVO Stock | USD 4.09 5.92 59.14% |
Aptevo Therapeutics is presently reporting on over 107 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 6.37 or Days Sales Outstanding of 277 will help investors to properly organize and evaluate Aptevo Therapeutics financial condition quickly.
Aptevo |
About Aptevo Financial Ratios Analysis
Aptevo TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Aptevo Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Aptevo financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Aptevo Therapeutics history.
Aptevo Therapeutics Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Aptevo Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Aptevo Therapeutics sales, a figure that is much harder to manipulate than other Aptevo Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Operating Cash Flow Per Share
A measure of the cash generated from a company's normal business operations per share, indicating how much cash is generated from a company's business operations on a per-share basis.Roic
Return on Invested Capital, a profitability ratio that measures the return that an investment generates for those who have provided capital, such as debt holders and equity holders.Most ratios from Aptevo Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Aptevo Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptevo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.At this time, Aptevo Therapeutics' Income Quality is very stable compared to the past year. As of the 13th of December 2024, Net Debt To EBITDA is likely to grow to 0.43, while Price To Sales Ratio is likely to drop 154.18.
| 2021 | 2022 | 2023 | 2024 (projected) | Days Sales Outstanding | 108.8 | 293.03 | 263.73 | 276.91 | PTB Ratio | 1.1K | 24.45 | 6.7 | 6.37 |
Aptevo Therapeutics fundamentals Correlations
Click cells to compare fundamentals
Aptevo Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Aptevo Therapeutics fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 30.5 | 1.1K | 111.05 | 141.13 | 162.3 | 154.18 | |
| Ptb Ratio | 83.51 | 277.1 | 1.1K | 24.45 | 6.7 | 6.37 | |
| Book Value Per Share | 178.62 | 215.32 | 11.41 | 154.47 | 43.95 | 41.75 | |
| Free Cash Flow Yield | (0.0496) | (0.043) | (0.006395) | (0.0164) | (0.0479) | (0.14) | |
| Operating Cash Flow Per Share | (639.3) | (380.43) | (203.47) | (180.67) | (42.19) | (44.29) | |
| Stock Based Compensation To Revenue | 0.0493 | 0.29 | 0.13 | 0.58 | 0.67 | 0.8 | |
| Capex To Depreciation | 0.0685 | 0.0626 | 0.62 | 0.0322 | 0.037 | 0.0352 | |
| Pb Ratio | 83.51 | 277.1 | 1.1K | 24.45 | 6.7 | 6.37 | |
| Ev To Sales | 30.83 | 1.1K | 108.75 | 136.92 | 123.23 | 175.54 | |
| Free Cash Flow Per Share | (641.61) | (381.57) | (210.17) | (180.92) | (42.19) | (44.29) | |
| Roic | (1.21) | (0.39) | (1.2) | (8.13) | (2.36) | (2.48) | |
| Inventory Turnover | 3.25 | 3.73 | 6.16 | 0.57 | 0.52 | 0.49 | |
| Net Income Per Share | (610.11) | (239.38) | (256.35) | 366.71 | (62.62) | (65.75) | |
| Days Of Inventory On Hand | 112.45 | 97.79 | 59.23 | 636.42 | 731.88 | 768.48 | |
| Payables Turnover | 0.96 | 3.1 | 3.2 | 5.49 | 0.26 | 0.14 | |
| Research And Ddevelopement To Revenue | 0.76 | 4.14 | 1.55 | 5.74 | 6.6 | 6.27 | |
| Capex To Revenue | 0.004719 | 0.0204 | 0.058 | 0.009313 | 0.0107 | 0.0102 | |
| Cash Per Share | 187.76 | 518.76 | 422.77 | 194.53 | 60.79 | 57.75 | |
| Pocfratio | (23.33) | (156.84) | (62.97) | (20.91) | (6.99) | (7.33) | |
| Capex To Operating Cash Flow | (0.00361) | (0.003002) | (0.0329) | (0.00138) | (0.001242) | (0.001304) | |
| Pfcf Ratio | (23.25) | (156.37) | (60.96) | (20.88) | (6.99) | (7.33) | |
| Days Payables Outstanding | 117.74 | 114.15 | 66.53 | 1.4K | 2.6K | 2.7K | |
| Income Quality | 1.05 | 1.65 | 0.76 | (2.62) | 0.67 | 0.71 | |
| Roe | (3.42) | (1.11) | (22.46) | 2.37 | (1.42) | (1.5) | |
| Ev To Operating Cash Flow | (23.59) | (156.41) | (61.66) | (20.28) | (6.0) | (6.3) | |
| Pe Ratio | (24.45) | (249.25) | (49.98) | 10.3 | (4.71) | (4.94) | |
| Return On Tangible Assets | (0.83) | (0.34) | (0.48) | 1.25 | (0.7) | (0.74) | |
| Ev To Free Cash Flow | (23.5) | (155.94) | (59.7) | (20.25) | (6.0) | (6.3) | |
| Earnings Yield | (0.0409) | (0.004012) | (0.02) | 0.0971 | (0.21) | (0.2) | |
| Net Debt To E B I T D A | (0.27) | 0.48 | 1.4 | 0.47 | 0.41 | 0.43 | |
| Current Ratio | 0.78 | 3.25 | 1.51 | 3.15 | 2.64 | 2.95 | |
| Tangible Book Value Per Share | 111.95 | 215.32 | 11.41 | 154.47 | 43.95 | 41.75 | |
| Graham Number | 1.6K | 1.1K | 256.57 | 1.1K | 248.84 | 236.4 | |
| Shareholders Equity Per Share | 178.62 | 215.32 | 11.41 | 154.47 | 43.95 | 41.75 | |
| Debt To Equity | 1.68 | 1.51 | 12.64 | 0.19 | 0.17 | 0.16 | |
| Capex Per Share | 2.31 | 1.14 | 6.69 | 0.25 | 0.29 | 0.27 |
Pair Trading with Aptevo Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aptevo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aptevo Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Aptevo Stock
| 0.54 | IMAB | I Mab | PairCorr |
| 0.43 | GNFT | Genfit | PairCorr |
| 0.38 | FLGC | Flora Growth Corp | PairCorr |
| 0.38 | LLY | Eli Lilly | PairCorr |
| 0.36 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
The ability to find closely correlated positions to Aptevo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aptevo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aptevo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aptevo Therapeutics to buy it.
The correlation of Aptevo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aptevo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aptevo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aptevo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptevo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptevo Therapeutics. If investors know Aptevo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptevo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (415.99) | Quarterly Revenue Growth (1.00) | Return On Assets (0.73) | Return On Equity (2.51) |
The market value of Aptevo Therapeutics is measured differently than its book value, which is the value of Aptevo that is recorded on the company's balance sheet. Investors also form their own opinion of Aptevo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aptevo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptevo Therapeutics' market value can be influenced by many factors that don't directly affect Aptevo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptevo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptevo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptevo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.